19th Ave New York, NY 95822, USA
Join Now
  1. Samples, H., Williams, A. R., Crystal, S., & Olfson, M. (2020). Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid. Health Affairs, 39(5), 747–755. https://doi.org/10.1377/hlthaff.2019.01085
  2. Chilcoat, H. D., Amick, H. R., Sherwood, M. R., & Dunn, K. E. (2019). Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Journal of Substance Abuse Treatment, 104, 148–157. https://doi.org/10.1016/j.jsat.2019.07.005
  3. Cicero, T. J., Ellis, M. S., & Chilcoat, H. D. (2018). Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence, 193, 117–123. https://doi.org/10.1016/j.drugalcdep.2018.09.007
  4. Dart, R. C. (2020). A new frontier: Prescription drug abuse beyond opioids. Presented at: Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System 14th Annual Scientific Meeting. Retrieved from https://www.radars.org/system/events/RADARS%20System%202020%20Annual%20Meeting_Dart.pdf.tmp
  5. Department of Justice, Drug Enforcement Administration, Office of the Administrator. (2023, January 12). Elimination of the DATA-Waiver Program [Dear Registrant Letter]. Retrieved from https://www.deadiversion.usdoj.gov/pubs/docs/A-23-0020-Dear-Registrant-Letter-Signed.pdf
  6. Department of Health and Human Services (HHS). (2024, November 20). Prescribing controlled substances via telehealth. Retrieved from https://telehealth.hhs.gov/providers/telehealth-policy/prescribing-controlled-substances-via-telehealth
  7. Carroll, J. J., Rich, J. D., & Green, T. C. (2018). The more things change: Buprenorphine/naloxone diversion continues while treatment remains inaccessible. Journal of Addiction Medicine, 12(6), 459–465. https://doi.org/10.1097/ADM.0000000000000436
  8. Strickland, D. M., & Burson, J. K. (2018). Sublingual absorption of naloxone in a large clinical population. Journal of Drug Metabolism & Toxicology, 9(02), 240. Retrieved from https://www.longdom.org/open-access/sublingual-absorption-of-naloxone-in-a-large-clinical-population-25281.html
  9. Blazes, C. K., & Morrow, J. D. (2020). Reconsidering the usefulness of adding naloxone to buprenorphine. Frontiers in Psychiatry, 11, 958. https://doi.org/10.3389/fpsyt.2020.00958
  10. Linke, S., Harrison, R., & Wallace, P. (2005). A web-based intervention used in general practice for people with excessive alcohol consumption. Journal of Telemedicine and Telecare, 11(Suppl 1), 39–41. https://doi.org/10.1258/1357633054461895
  11. Debelak, K., Morrone, W. R., O’Grady, K. E., & Jones, H. E. (2013). Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy: Initial patient care and outcome data. The American Journal on Addictions, 22(3), 252–254. https://pubmed.ncbi.nlm.nih.gov/23617867/
  12. Project CARA. (2021). Use of buprenorphine-naloxone in pregnancy. (Project CARA Brief).
  13. Etminan, M., Rezaeianzadeh, R., Kezouh, A., & Aminzadeh, K. (2022). Association between sublingual buprenorphine-naloxone exposure and dental disease. JAMA, 328(22), 2269–2271. https://doi.org/10.1001/jama.2022.17485
  14. Drug Enforcement Administration (DEA). (2022). DEA’s commitment to expanding access to medication-assisted treatment. Retrieved from https://www.dea.gov/press-releases/2022/03/23/deas-commitment-expanding-access-medication-assisted-treatment
  15. Centers for Disease Control and Prevention (CDC). (n.d.). Buprenorphine dispensing maps. Retrieved from https://www.cdc.gov/overdose-prevention/data-research/facts-stats/buprenorphine-dispensing-maps.html
  16. Ostrach, B., Hill, L., Carpenter, D., & Pollini, R. (2023). Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility. Journal of the American Pharmacists Association, 63(4), 1044–1048. https://doi.org/10.1016/j.japh.2023.04.029
  17. Chambers, L. C., et al. (2023). Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Network Open, 6(9), e2334540. https://doi.org/10.1001/jamanetworkopen.2023.34540
  18. Samples, H., et al. (2023). Buprenorphine after nonfatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries. American Journal of Preventive Medicine, 65(1), 19–29. https://doi.org/10.1016/j.amepre.2023.01.037
  19. Woody, G., et al. (2014). HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial. Journal of Acquired Immune Deficiency Syndromes, 66(3), 288–293. https://doi.org/10.1097/QAI.0000000000000165
  20. Evans, E. A., et al. (2019). Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction, 114(8), 1396–1404. https://doi.org/10.1111/add.14620
  21. Boston Federal Reserve Bank. (2023). New report: Buprenorphine treatment may improve job-finding rates of people with opioid use disorder. Retrieved from https://www.bostonfed.org/news-and-events/news/2023/01/opioid-use-disorder-treatment-buprenorphine-oud-employment-mary-burke-riley-sullivan-boston-fed.aspx
  22. Carroll, J. J., Rich, J. D., & Green, T. C. (2018). The more things change: Buprenorphine/naloxone diversion continues while treatment remains inaccessible. Journal of Addiction Medicine, 12(6), 459–465. https://doi.org/10.1097/ADM.0000000000000436
  23. Williams, A. R., Samples, H., Crystal, S., & Olfson, M. (2020). Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. American Journal of Psychiatry, 177(2), 117–124.
  24. Davoli, M., Perucci, C. A., Forastiere, F., et al. (1993). Risk factors for overdose mortality: A case-control study within a cohort of intravenous drug users. International Journal of Epidemiology, 22(2), 273–277.
  25. Ma, J., Bao, Y. P., Wang, R. J., et al. (2019). Effects of medication-assisted treatment on mortality among opioid users: A systematic review and meta-analysis. Molecular Psychiatry, 24(12), 1868–1883. https://doi.org/10.1038/s41380-018-0094-5
  26. American Pharmacists Association. (2020). Actions of the 2020 House of Delegates – Special session. Journal of the American Pharmacists Association, 60(5), e9–e16. https://doi.org/10.1016/j.japh.2020.08.015
  27. North Carolina Board of Pharmacy. (2023). Guidance on implementation of STOP Act. Retrieved from https://www.ncbop.org/downloads/GuidanceImplementationSTOPACTUpdatedJune2023.pdf
  28. Drug Enforcement Administration (DEA) & Health and Human Services (HHS). (2025). DEA and HHS extend telemedicine flexibilities through 2025. Retrieved from https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025
  29. National Institutes of Health (NIH). (2023). Telehealth supports retention in treatment for opioid use disorder. Retrieved from https://www.nih.gov/news-events/news-releases/telehealth-supports-retention-treatment-opioid-use-disorder
  30. Ecker, J., et al. (2019). Substance use disorders in pregnancy: Clinical, ethical, and research imperatives of the opioid epidemic. American Journal of Obstetrics & Gynecology, 221(1), B5–B28. https://doi.org/10.1016/j.ajog.2019.03.022
  31. American Society of Addiction Medicine (ASAM). (2025). The ASAM national practice guideline for the treatment of opioid use disorder – 2020 focused update. Retrieved from https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline
  32. North Carolina Administrative Code. (n.d.). Emergency prescription refills (21 NCAC 46.1809). Retrieved from http://reports.oah.state.nc.us/ncac/title%2021%20-%20occupational%20licensing%20boards%20and%20commissions/chapter%2046%20-%20pharmacy/21%20ncac%2046%20.1809.pdf